New Drug Approvals Archive - April 2012
Levemir (insulin detemir )
Labeling Revision Approved: March 29, 2012
New Indication Approved: April 2, 2012
Read more: Neupro (rotigotine) FDA Approval History
Amyvid (florbetapir F 18) Injection
Date of Approval: April 6, 2012
Company: Eli Lilly and Company and Avid Radiopharmaceuticals, Inc.
Treatment for: Diagnostic
Amyvid (florbetapir F 18) is a radioactive diagnostic agent used for brain imaging of beta-amyloid plaques in patients who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.
- FDA Approves Amyvid (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline
Labeling Revision Approved: April 6, 2012
Read more: Victoza (liraglutide) FDA Approval History
Labeling Revision Approved: April 26, 2012
- Novartis drug Afinitor approved by FDA as first medication to treat patients with non-cancerous kidney tumors associated with TSC
Read more: Afinitor (everolimus) FDA Approval History
New Indication Approved: April 26, 2012
Read more: Votrient (pazopanib) FDA Approval History
Stendra (avanafil) Tablets
Date of Approval: April 27, 2012
Company: Vivus, Inc.
Treatment for: Erectile Dysfunction
Stendra (avanafil) is a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).
Read more: Stendra (avanafil) FDA Approval History
New Indication Approved: April 27, 2012